What is Abaxis?
Founded in 1989 and headquartered in Union City, California, Abaxis operates as a global leader in the development and distribution of portable blood analysis systems. The company occupies a critical niche in the healthcare technology landscape, providing point-of-care solutions that facilitate immediate blood constituent measurements. By streamlining the diagnostic process, Abaxis enhances the efficiency of care delivery, allowing medical professionals to make informed, real-time decisions. Their dual-market approach, serving both human clinical specialties and veterinary practices, provides a robust foundation for sustained market relevance and technological evolution.
How much funding has Abaxis raised?
Abaxis has raised a total of $23.9M across 1 funding round:
Stock Offering
$23.9M
Stock Issuance/Offering (1992): $23.9M, investors not publicly disclosed
Key Investors in Abaxis
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Abaxis?
With the successful deployment of this major strategic investment, Abaxis is positioned to accelerate its research and development pipeline, focusing on the next generation of diagnostic hardware. The company's trajectory suggests a shift toward deeper integration of its portable systems within modern clinical workflows, potentially expanding its footprint in decentralized healthcare settings. As the demand for rapid, accurate diagnostic data continues to rise, Abaxis is well-equipped to leverage its established manufacturing infrastructure to meet global market requirements. Future growth will likely be driven by continued innovation in blood analysis precision and the expansion of its service network to support a broader range of medical and veterinary applications.
See full Abaxis company page
